Search This Blog

Wednesday, October 7, 2026

FDA grants two Breakthrough Therapy Designations to AbbVie

 investigational ADC telisotuzumab adizutecan (Temab-A) in colorectal and non-small cell lung cancer

https://finviz.com/stock?t=ABBV&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)